参考文献/References:
[1] Page SP, Herring N, Hunter RJ, et al. Periprocedural stroke risk in patients undergoing catheter ablation for atrial fibrillation on uninterrupted warfarin[J].J Cardiovasc Electrophysiol,2014,25(6):585-590.
[2] Noseworthy PA, Kapa S, Deshmukh AJ, et al. Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: a propensity-matched study of 24,244 patients[J]. Heart Rhythm,2015,12(6):1154-1161.
[3] Deneke T, Jais P, Scaglione M, et al. Silent cerebral events/lesions related to atrial fibrillation ablation:a clinical review[J].J Cardiovasc Electrophysiol, 2015,26(4):455-463.
[4] Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design[J]. Europace,2012,14(4):528-606.
[5] Mccready JW, Nunn L, Lambiase PD, et al. Incidence of left atrial thrombus prior to atrial fibrillation ablation: is preprocedural transoesophageal echocardiography mandatory?[J]. Europace,2010,12(7):927-932.
[6] Steinberg BA, Hammill BG, Daubert JP, et al. Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation[J]. Heart, 2014,100(23):1871-1877.
[7] Bhagirath P, van der Graaf AW, Karim R, et al. Multimodality imaging for patient evaluation and guidance of catheter ablation for atrial fibrillation—current status and future perspective[J]. Int J Cardiol,2014,175(3):400-408.
[8] Hussein AA, Martin DO, Saliba W, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy[J]. Heart Rhythm,2009,6(10):1425-1429.
[9] di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation:the impact of periprocedural therapeutic international normalized ratio[J]. Circulation,2010,121(23):2550-2556.
[10] Santangeli P, di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications:evidence from a meta-analysis[J]. Circ Arrhythm Electrophysiol,2012,5(2):302-311.
[11] di Biase L, Gaita F, Toso E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study[J]. Heart Rhythm, 2014,11(5):791-798.
[12] di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation(AF)Patients Undergoing Catheter Ablation(COMPARE)randomized trial[J].Circulation,2014, 129(25):2638-2644.
[13] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009,361(12):1139-1151.
[14] Lakkireddy D, Reddy YM, di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation:results from a multicenter prospective registry[J]. J Am Coll Cardiol,2012,59(13):1168-1174.
[15] Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation[J]. J Cardiovasc Electrophysiol,2012,23(3):264-268.
[16] Steinberg BA, Holmes DN, Piccini JP, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation:a meta-analysis of observational studies[J]. J Interv Card Electrophysiol, 2013,37(3):213-221.
[17] Eitel C, Koch J, Sommer P, et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation[J]. Europace, 2013,15(11):1587-1593.
[18] Lakkireddy D, Reddy YM, di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation[J]. J Am Coll Cardiol, 2014,18(10):982-988.
[19] Ouyang F, Tilz R, Chun J, et al.Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up[J]. Circulation, 2010,122(23):2368-2377.
[20] Chao TF, Ambrose K, Tsao HM, et al. Relationship between the CHADS(2)score and risk of very late recurrences after catheter ablation of paroxysmal atrial fibrillation[J]. Heart Rhythm,2012,9(8):1185-1191.
[21] Uchiyama T, Miyazaki S, Taniguchi H, et al. Six-year follow-up of catheter ablation in paroxysmal atrial fibrillation[J]. Circ J,2013,77(11):2722-2727.
[22] Chao TF, Tsao HM, Lin YJ, et al. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation:results of 3-year follow-up[J]. Circ Arrhythm Electrophysiol,2012,5(3):514-520.
[23] Tilz RR, Rillig A, Thum AM, et al. Catheter ablation of long-standing persistent atrial fibrillation:5-year outcomes of the Hamburg Sequential Ablation Strategy[J]. J Am Coll Cardiol,2012,60(19):1921-1929.
[24] Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol,2008,51(8):843-849.
[25] Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation[J]. J Am Coll Cardiol,2010,55(8):735-743.
[26] Yagishita A, Takahashi Y, Takahashi A, et al. Incidence of late thromboembolic events after catheter ablation of atrial fibrillation[J]. Circ J, 2011,75(10):2343-2349.
[27] Uhm JS, Won H, Joung B, et al. Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation[J]. Yonsei Med J,2014,55(5):1238-1245.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(6):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[3]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[4]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[5]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[6]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[7]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(6):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[8]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(6):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[9]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(6):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[10]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(6):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
[11]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(6):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]